Informations générales (source: ClinicalTrials.gov)
A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors
Interventional
Phase 1
Dragonfly Therapeutics (Voir sur ClinicalTrials)
novembre 2023
décembre 2027
29 juin 2024
DF6215-001 is a study of a modified human cytokine (interleukin-2; IL-2) that retains the
ability to bind to a certain part of the IL-2 receptor on a subset of white blood cells
(lymphocytes), which can help recognize and kill tumor cells. The study will occur in two
phases. The first phase will be a dose escalation phase, enrolling patients with various
types of solid tumors. The second phase, Phase 1b, will include a dose expansion using
the best dose selected from the first phase of the study. A cohort will be opened with
eligible patients having a select solid tumor.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/12/2024 12:44:11 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Institut Paoli-Calmettes - 13009 - Marseille - France | Cecile Vicier, M.D. | Contact (sur clinicalTrials) | |||
Critères
Tous
Key Inclusion Criteria - General (applies to all cohorts)
- Signed written informed consent
- Male or female patients aged ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study
entry and an estimated life expectancy of at least 3 months
- Adequate hematological function
- Adequate cardiac function
- Effective contraception
Inclusion Criteria - 3+3 Dose Escalation
- Histologically or cytologically proven locally advanced or metastatic solid tumor,
for which no standard therapy exists, or standard therapy has failed
- Evidence of objective disease (but participation does not require a measurable
lesion)
- Archived tumor biopsy. If archival tissue is unavailable, a fresh tumor biopsy is
required, obtained within the screening window.
Inclusion Criteria - Safety/PK/PD
- Histologically or cytologically proven locally advanced or metastatic solid tumor
from the following list, where standard therapy does not exist or has failed:
- Melanoma
- HPV-positive advanced malignancies
- Ovarian cancer
- Head and neck cancer
- Lung cancer (non-small-cell lung cancer [NSCLC])
- Renal cell carcinoma (RCC)
- Other tumor types may be eligible after discussion with the Sponsor medical
monitor
- Disease must be measurable with at least 1 unidimensional measurable lesion by
RECIST 1.1
- A fresh tumor biopsy must be obtained during the screening window and on-treatment
Inclusion Criteria - Efficacy Expansion
- Disease must be measurable with at least 1 unidimensional measurable lesion by
RECIST 1.1
- A fresh tumor biopsy must be obtained during the screening window and on-treatment
Key Exclusion Criteria - General (applies to all cohorts)
- Patients receiving chemotherapy, radiotherapy (other than palliative bone-directed
radiotherapy), major surgery, or receiving another therapeutic agent within 28 days
before the start of study drug or within 5 half-lives of the previous therapeutic
agent (if known), whichever is shorter
- Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy [except for
palliative bone-directed radiotherapy], immune therapy, or cytokine therapy [except
for erythropoietin]), major surgery (excluding prior diagnostic biopsy), concurrent
systemic therapy with steroids or other immunosuppressive agents, or use of any
investigational drug within 28 days before the start of treatment or within 5
half-lives of the previous therapeutic agent (if known), whichever is shorter.
Short-term administration of systemic steroids (eg, for allergic reactions or the
management of immune-related adverse events [irAEs]) is allowed.
- Note: Patients receiving bisphosphonate or denosumab are eligible, provided
treatment was initiated at least 14 days before the first dose of DF6215
- Previous malignant disease (other than the target malignancy to be investigated in
this study) within the last 3 years, with the exception of basal or squamous cell
carcinoma of the skin, low-grade prostate cancer (Gleason score ≤ 6 and must be
Stage I or II), or cervical carcinoma in situ
- Life expectancy of less than 3 months
- Patients with brain metastases are excluded, unless all of the following criteria
are met:
- Central nervous system (CNS) lesions are asymptomatic and previously treated
- Patient does not require ongoing daily steroid treatment for replacement for
adrenal insufficiency (except ≤ 10 mg prednisone [or equivalent])
- Imaging demonstrates stable disease 28 days after last treatment
- Receipt of any organ transplant, including autologous or allogeneic stem-cell
transplantation
- Pregnancy or lactation during the study
- Signed written informed consent
- Male or female patients aged ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study
entry and an estimated life expectancy of at least 3 months
- Adequate hematological function
- Adequate cardiac function
- Effective contraception
Inclusion Criteria - 3+3 Dose Escalation
- Histologically or cytologically proven locally advanced or metastatic solid tumor,
for which no standard therapy exists, or standard therapy has failed
- Evidence of objective disease (but participation does not require a measurable
lesion)
- Archived tumor biopsy. If archival tissue is unavailable, a fresh tumor biopsy is
required, obtained within the screening window.
Inclusion Criteria - Safety/PK/PD
- Histologically or cytologically proven locally advanced or metastatic solid tumor
from the following list, where standard therapy does not exist or has failed:
- Melanoma
- HPV-positive advanced malignancies
- Ovarian cancer
- Head and neck cancer
- Lung cancer (non-small-cell lung cancer [NSCLC])
- Renal cell carcinoma (RCC)
- Other tumor types may be eligible after discussion with the Sponsor medical
monitor
- Disease must be measurable with at least 1 unidimensional measurable lesion by
RECIST 1.1
- A fresh tumor biopsy must be obtained during the screening window and on-treatment
Inclusion Criteria - Efficacy Expansion
- Disease must be measurable with at least 1 unidimensional measurable lesion by
RECIST 1.1
- A fresh tumor biopsy must be obtained during the screening window and on-treatment
Key Exclusion Criteria - General (applies to all cohorts)
- Patients receiving chemotherapy, radiotherapy (other than palliative bone-directed
radiotherapy), major surgery, or receiving another therapeutic agent within 28 days
before the start of study drug or within 5 half-lives of the previous therapeutic
agent (if known), whichever is shorter
- Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy [except for
palliative bone-directed radiotherapy], immune therapy, or cytokine therapy [except
for erythropoietin]), major surgery (excluding prior diagnostic biopsy), concurrent
systemic therapy with steroids or other immunosuppressive agents, or use of any
investigational drug within 28 days before the start of treatment or within 5
half-lives of the previous therapeutic agent (if known), whichever is shorter.
Short-term administration of systemic steroids (eg, for allergic reactions or the
management of immune-related adverse events [irAEs]) is allowed.
- Note: Patients receiving bisphosphonate or denosumab are eligible, provided
treatment was initiated at least 14 days before the first dose of DF6215
- Previous malignant disease (other than the target malignancy to be investigated in
this study) within the last 3 years, with the exception of basal or squamous cell
carcinoma of the skin, low-grade prostate cancer (Gleason score ≤ 6 and must be
Stage I or II), or cervical carcinoma in situ
- Life expectancy of less than 3 months
- Patients with brain metastases are excluded, unless all of the following criteria
are met:
- Central nervous system (CNS) lesions are asymptomatic and previously treated
- Patient does not require ongoing daily steroid treatment for replacement for
adrenal insufficiency (except ≤ 10 mg prednisone [or equivalent])
- Imaging demonstrates stable disease 28 days after last treatment
- Receipt of any organ transplant, including autologous or allogeneic stem-cell
transplantation
- Pregnancy or lactation during the study